JAT is is expected to do minimum A$100m in revenues at margins of 32.5% in FY 2021 with a market capitalization of only A$28m. That is simply returning to pre covid levels, increased margins and adding in the latest $32m deal with SPT.
JAT's revenues could increase exponentially above this from February onwards for three (3) reasons:
1. 1,000 Wumart stores start selling JAT products; 2. JAT will open a physical store in Shanghai selling their product range including new Abbeyard (A2 protein) to compete with A2M; 3, JAT will launch an online retail store to allow customers to purchase direct.
There is no other ASX listed company that sells infant milk products to have a physical store in China. A2M, BAL, BUB all ship or use daigou sellers. JAT is the first to achieve this and will open the doors later this month. JAT will have stocks filled in Shanghai with products that compete with A2M. It's expected the store will sell out of all it can produce and stock.
Consider that JAT was on track to do A$100m in revenues in 2021 using previous sales channels. This doesn't factor in growth from a physical store in Shanghai and online retail store. The growth here could be exponential.
